文献速递儿童血液肿瘤与免疫

儿童KMT2A基因重排前体淋巴细胞肿瘤的临床特征与预后

[Clinical characteristics and prognosis of pediatric precursor lymphoid neoplasms with KMT2A gene rearrangement].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2026-01-01

该回顾性队列研究纳入47例伴KMT2A基因重排的儿童前体淋巴细胞肿瘤患儿,发现该病呈高度侵袭性、预后差,3年总生存率与无事件生存率分别为(68.2±7.3)%和(51.7±8.0)%。诱导治疗第12周qPCR-MRD阴性和HSCT是EFS的独立保护因素,CR1期移植组生存率显著优于化疗组。

要点

  • 伴KMT2A基因重排儿童前体淋巴细胞肿瘤高度侵袭、预后差。
  • 诱导第12周qPCR-MRD阴性和HSCT是EFS独立保护因素。
  • CR1期移植组3年生存率显著优于CR1期化疗组。

核心结论

  • 伴KMT2A基因重排的儿童前体淋巴细胞肿瘤呈高度侵袭性、预后差。
  • 诱导治疗第12周qPCR-MRD阴性和HSCT是EFS的独立保护因素。

研究设计与样本

  • 回顾性队列研究,收集2018年1月至2024年11月郑州大学附属儿童医院47例伴KMT2A基因重排前体淋巴细胞肿瘤患儿临床资料。
  • 根据CR1期是否接受HSCT分为CR1期移植组与CR1期化疗组,比较生存率并分析预后因素。
  • CR1期化疗组复发患儿按挽救治疗方式分为移植挽救治疗组与化疗挽救治疗组,比较复发后生存率。

主要发现

  • 47例中男27例、女20例,年龄0.8(0.4,2.4)岁,急性B淋巴细胞白血病40例(85%)。
  • 初诊白细胞计数89×10⁹(27×10⁹,302×10⁹)/L,46例评估中枢状态中10例(22%)合并中枢神经系统白血病。
  • 43例纳入疗效评估,随访30.1(13.8,47.7)个月,3年总生存率与EFS分别为(68.2±7.3)%和(51.7±8.0)%。
  • CR1期移植组(17例)3年总生存率和EFS高于CR1期化疗组(26例)[100.0%比(47.2±10.1)%、(84.7±10.3)%比(29.6±9.1)%,χ²=12.68、16.03,均P<0.001]。
  • 移植挽救治疗组(4例)18个月总生存率高于化疗挽救治疗组(14例)[100.0%比(8.9±8.4)%,χ²=10.07,P=0.002]。

关键数值与推荐

  • 多因素Cox回归显示诱导治疗第12周qPCR-MRD阴性是EFS独立保护因素(HR=0.29,95%CI 0.10~0.83,P=0.022)。
  • HSCT是EFS独立保护因素(HR=0.15,95%CI 0.05~0.44,P<0.001)。

临床怎么用

  • 对伴KMT2A基因重排的儿童前体淋巴细胞肿瘤应认识其高度侵袭性和不良预后。
  • 诱导治疗第12周qPCR-MRD阴性提示预后较好,可作为预后评估指标。
  • CR1期接受HSCT可显著改善生存,临床可考虑作为治疗选择。

局限性

  • 本研究为单中心回顾性队列研究,样本量47例。
  • 移植挽救治疗组仅4例,化疗挽救治疗组14例,亚组样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical characteristics and prognostic factors of pediatric precursor lymphoid neoplasms with KMT2A gene rearrangement. Methods: In this retrospective cohort study, clinical data of 47 children with KMT2A gene rearrangement precursor lymphoid neoplasms diagnosed at the Children's Hospital Affiliated to Zhengzhou University from January 2018 to November 2024 were collected, so as to describe their clinical characteristics. According to whether hematopoietic stem cell transplantation (HSCT) was performed during first complete remission (CR1), children were divided into CR1 transplantation group and CR1 chemotherapy group, survival rates comparison and prognostic factor analysis were performed between two groups. For relapsed children in the CR1 chemotherapy group, they were further subdivided into a transplantation salvage group and a chemotherapy salvage group based on salvage therapy modality, and post-relapse survival rates were compared between the two subgroups. Survival rates were calculated using the Kaplan-Meier method and compared using the log-rank test. Prognostic factors were analyzed using the Cox proportional hazards regression model. Results: Among the 47 patients, there were 27 males and 20 females, with the age of 0.8 (0.4, 2.4) years. B-cell acute lymphoblastic leukemia accounted for 85% (40 cases). The initial white blood cell count was 89×10⁹ (27×10⁹, 302×10⁹)/L. Central nervous system leukemia was diagnosed in 10 children(22%, 46 children had central nervous system assessment). A total of 43 children were included in the efficacy evaluation, with a follow-up of 30.1 (13.8, 47.7) months. The 3-year overall survival and event-free survival (EFS) rates were (68.2±7.3) % and (51.7±8.0) %, respectively. The CR1 transplantation group (17 children) had significantly better 3-year overall survival and EFS rates than the CR1 chemotherapy group (26 children)(100.0% vs. (47.2±10.1) %, (84.7±10.3) % vs. (29.6±9.1) %, χ²=12.68 and 16.03, both P<0.001). The transplantation salvage group (4 children) had a higher 18-month overall survival rate than the chemotherapy salvage group (14 children) (100.0% vs. (8.9±8.4)%, χ²=10.07, P=0.002). Multivariate analysis showed that negativity of minimal residual disease detected by quantitative real-time PCR (qPCR-MRD) at week 12 of induction therapy (HR=0.29, 95%CI 0.10-0.83, P=0.022) and HSCT (HR=0.15, 95%CI 0.05-0.44, P<0.001) were both independent protective factors for EFS. Conclusion: Pediatric KMT2A gene rearrangement precursor lymphoid neoplasms are clinically highly aggressive and have a poor prognosis, but negative qPCR-MRD at week 12 of induction therapy and HSCT are independent protective factors for EFS. 目的: 探讨伴KMT2A基因重排儿童前体淋巴细胞肿瘤的临床特征及预后因素。 方法: 回顾性队列研究。收集并分析2018年1月至2024年11月郑州大学附属儿童医院收治的47例伴KMT2A基因重排前体淋巴细胞肿瘤患儿的临床特征。根据第1次完全缓解(CR1)期是否接受异基因造血干细胞移植(HSCT)治疗分为CR1期移植组与CR1期化学治疗(简称化疗)组,比较两组患儿的生存率并进行预后因素分析;根据挽救治疗方式将CR1期化疗组中复发患儿分为移植挽救治疗组与化疗挽救治疗组,比较两组患儿复发后的生存率。采用Kaplan-Meier法计算生存率并行Log-Rank检验,Cox比例风险回归模型分析预后因素。 结果: 47例患儿中男27例、女20例,年龄0.8(0.4,2.4)岁,急性B淋巴细胞白血病40例(85%),初诊时白细胞计数89×10⁹(27×10⁹,302×10⁹)/L。46例患儿评估中枢状态,10例(22%)合并中枢神经系统白血病。43例纳入疗效评估,随访30.1(13.8,47.7)个月,3年总生存率、无事件生存率(EFS)分别为(68.2±7.3)%、(51.7±8.0)%。CR1期移植组(17例)3年总生存率、EFS高于CR1期化疗组(26例)[100.0%比(47.2±10.1)%、(84.7±10.3)%比(29.6±9.1)%,χ²=12.68、16.03,均P<0.001]。移植挽救治疗组(4例)18个月总生存率高于化疗挽救治疗组(14例)[100.0%比(8.9±8.4)%,χ²=10.07,P=0.002]。多因素Cox回归分析显示,诱导治疗第12周实时荧光定量PCR检测的微小残留病(qPCR-MRD)阴性(HR=0.29,95%CI 0.10~0.83,P=0.022)与HSCT(HR=0.15,95%CI 0.05~0.44,P<0.001)是EFS的独立保护因素。 结论: 伴KMT2A基因重排的儿童前体淋巴细胞肿瘤呈高度侵袭性、预后差,但诱导治疗第12周qPCR-MRD阴性和HSCT是EFS的独立保护因素。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu YY, Ma P, He YY, et al. [Clinical characteristics and prognosis of pediatric precursor lymphoid neoplasms with KMT2A gene rearrangement]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42527137. doi:10.3760/cma.j.cn112140-20251229-01155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。